Picture 1 of 1

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals by John Geigert (Paperback, 2016)

BOOKS etc. (529861)

99.5% positive Feedback

Price:

£122.05

Free postage

Estimated delivery Tue, 24 Jun - Tue, 1 Jul

Returns:

60 days return. Buyer pays for return postage. If you use an eBay delivery label, it will be deducted from your refund amount.

Condition:

New

ISBN-13: 9781493943999, 978-1493943999. It will put into perspective the need for a graded approach to QA/QC from early clinical trials through market approval.

About this product

Product Information

This book highlights the challenges facing quality assurance/quality control (QA/QC) in today's biopharmaceutical environment and presents the strategic importance and value generated by QA/QC for their involvement in control of manufacturing. It will put into perspective the need for a graded approach to QA/QC from early clinical trials through market approval. Since the first edition published in 2004, there have been more than 50 new regulatory guidances released by the Food and Drug Administration (FDA), European Medicines Agency (EMA) and ICH that affect the CMC regulatory compliance of biopharmaceuticals; also the application of biosimilars has been developed in Europe and is under development in the USA. The revised update will be broadened to include not only biopharmaceuticals (biotech drugs) but also other biologics (vaccines, cell therapy, plasma-derived proteins, etc.)